Global Prostate Cancer Therapeutics Market- Market Overview: 

The global prostate cancer therapeutics market is expected to grow from USD 10,600 million in 2022 to USD 19,619 million by 2030, at a CAGR of 8% during the Projection period 2023-2030. The growth of the prostate cancer therapeutics market is mainly driven by the increasing incidences of prostate cancer coupled with the adoption of novel screening and diagnostic technologies.

The most common type of non-cutaneous cancer worldwide is prostate cancer. The ageing population, the sedentary lifestyle of those in industrialised nations, and the early start of urological problems are all factors that contribute to the prevalence of prostate cancer globally. It is hoped that research and development initiatives meant to increase the emphasis on "patient-centric" care will promote innovation in the form of effective drugs and therapies. Patients' reliance on health insurance companies' availability and coverage of reimbursements, however, could put pressure on market participants. Prostate cancer treatments have significantly improved over the preceding ten years thanks to drugs like enzalutamide, abiraterone acetate, sipuleucel-T, cabazitaxel, and radium-233. The market is expanding as a result of factors such the rising incidence of prostate cancer, the adoption of cutting-edge screening and diagnostic tools, and government backing for novel prostate cancer treatments. It is anticipated that the use of novel screening and diagnostic technologies would encourage the use of treatments. Technology advancements in computational biology and bioinformatics have enabled recent therapeutic advances. With a targeted approach that incorporates proteome profiling, exome sequencing, and whole-genome sequencing, market participants have developed effective methods for creating novel cures and therapies. For instance, in a phase III trial for Olaparib that will enrol nearly 4,000 men in 2022, tumour genetic testing will be employed to identify patients.

Sample Request: - Global Prostate Cancer Therapeutics Market

Market Dynamics: 

Drivers:

• Rise in Prevalence

In industrialised nations with lower rates of morbidity, there are more elderly people, who are more susceptible to prostate cancer. Males over 65 make up the majority of prostate cancer cases, according to the Prostate Cancer Foundation. Thus, an ageing population, sedentary lifestyles in industrialised nations, and an increase in childhood obesity all contribute to the prevalence of prostate cancer worldwide. As a result, there is a greater need for and demand for prostate cancer treatments.

Restraints:         

• High Cost

Prostate cancer therapies market expansion will be hampered by high treatment costs and a low success rate for anticancer medications in clinical trials. The growth of the prostate cancer therapies market would also be hampered by the unfavourable effects associated with these treatments. Longer treatment times and lower awareness will present additional market challenges during the projected period.

Opportunities:

• Rise in Government Initiatives

Numerous universities and research institutions are funding studies to create medicinal solutions to treat these malignancies. For instance, many pipeline drugs that are now undergoing phase 2 studies, such as LY2452473 (Dana-Farber Cancer Institute), Avelumab (Duke University Medical Center), and Metformin (Mansoura University), are anticipated to hit the market soon. The market for generic prostate cancer therapies will also expand as a result of numerous medications whose patents are about to expire over the projected period. To increase the sales of their products, several pharmaceutical companies are concentrating on launching their individual medications in other nations.

Challenges:

• Some Disadvantages

One in five men who undergo surgery to remove their prostate experience bladder control loss. Furthermore, nearly two out of three men who undergo prostate surgery develop impotence, and roughly half of men who receive radiation therapy do as well.

Segmentation Analysis:

The global prostate cancer therapeutics market has been segmented based on drug type, distribution channel, and region.

By Drug Type

The drug type segment is chemotherapy, targeted therapy, hormonal therapy, immunotherapy, and others. The hormonal therapy segment led the largest share of the prostate cancer therapeutics market with a market share of around 37% in 2022. The majority of the medications used in hormonal therapy are anti-androgens, luteinizing hormone-releasing hormone (LHRH) antagonists, and luteinizing hormone-releasing hormone (LHRH) antagonists. Xtandi is one of the most widely used medications, and not simply because more individuals are receiving treatment for prostate cancer; instead, more patients are now taking it for longer periods of time; the typical length is now nine months. In 2021, the drug brought in more than 3 billion dollars. More urologists are expected to continue recommending the treatment, which will assist Xtandi's long-term revenue stream.

By Distribution Channel

The distribution channel segment is online pharmacies, hospital pharmacies, drug stores and  retail pharmacies. The hospital pharmacies segment led the largest share of the prostate cancer therapeutics market with a market share of around 45% in 2022. Hospital pharmacies and pharmacists are significant market players because they oversee pharmaceuticals in a demanding hospital environment where prompt access to medications and supplies is essential. Furthermore, because these pharmacies offer both in-patient and out-patient services, patients can easily get help for a range of ailments. Additionally, these pharmacies work to reduce clinical decision-making errors and prioritize making money from pharmaceutical sales while attempting to reduce prescription costs generally. Lutetium 177 therapy for prostate cancer patients was first made available by Royal Surrey in August 2022 as part of the Early Access Medicine Scheme (EAMS). The action was taken after The Medicines and Healthcare Products Regulatory Agency granted the product a marketing authorisation (MHRA).

Global Prostate Cancer Therapeutics Market - Sales Analysis.

The sale of the prostate cancer therapeutics market expanded at a CAGR of 5% from 2016 to 2022.

The unchecked cell proliferation in the prostate gland is what leads to prostate cancer. After skin cancer, prostate cancer is the most prevalent cancer in men in the United States. Prostate cancer is the second highest cause of mortality for males with cancer in the United States as of 2016, according to the American Community Survey. Adenocarcinomas make up almost all cases of prostate cancer (cancers that begin in cells that make and release mucus and other fluids). Sarcomas, small cell carcinomas, neuroendocrine tumours, and transitional cell carcinomas are a few other uncommon forms of prostate cancer. Men who have prostate cancer may experience symptoms including frequent urination or a weak urine flow, but similar symptoms can also be brought on by benign disorders of the prostate.

According to the American Cancer Society, there were approximately 26.730 fatalities and 161,360 new cases of prostate cancer in the United States in 2017. There is no proven technique to prevent prostate cancer because its source is unknown. All males over 40 should undergo an annual rectal exam, and men should start getting annual PSA tests at age 50, according to the American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN).

Thus, owing to the aforementioned factors, the global prostate cancer therapeutics market is expected to grow at a CAGR of 8% during the Projection period from 2023 to 2030.

By Regional Analysis:

The regions analyzed for the prostate cancer therapeutics market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region dominated the prostate cancer therapeutics market and held a 39% share of the market revenue in 2022. 

• The North America region witnessed a major share. since the disease is becoming more common and there is a great need for prostate cancer therapy items in the area. However, growth in North America is responsible for the introduction of promising new medications in the biologics and hormone therapy sectors. The anticipated launch of a few pipeline medications is anticipated to fuel the local market during the projection period. For instance, the Pluvicto medication, which will be used to treat adult patients with prostate cancer, received FDA approval for an advanced accelerator application in March 2022. Over the course of the Projection period, the market is expected to be driven by a solid pipeline and government backing for innovation.
• Asia-Pacific is anticipated to experience significant growth during the Projection period. Cost-effective therapy, customized medications, technical improvements, the availability of a wide range of treatment options, and the rising incidence of prostate malignancies are all credited with driving the market's expansion. For instance, Xtandi (enzalutamide), which is co-licensed by Pfizer in the United States and Astellas Pharma in Japan for the treatment of men with prostate cancer, is five times less expensive in Japan than it is in the United States. Over the course of the Projection period, technology developments and such cost-effective treatments are anticipated to drive market expansion.

Global Prostate cancer therapeutics market - Country Analysis:

• Germany

Germany's prostate cancer therapeutics market size was valued at USD 67.45 million in 2022 and is expected to reach USD 82.1 million by 2030, at a CAGR of 7.5% from 2023 to 2030. Due to the growing patient population, rising healthcare investment, and expanding government backing.

• China

China’s prostate cancer therapeutics market size was valued at USD 142.2 million in 2022 and is expected to reach USD 197.6 million by 2030, at a CAGR of 7.2% from 2023 to 2030. Due to the region's significant important player presence, high level of disposable income, and sophisticated healthcare system

• India

India's prostate cancer therapeutics market size was valued at USD 125.5 million in 2022 and is expected to reach USD 167.8 million by 2030, at a CAGR of 7.7% from 2023 to 2030. This can be attributed to patients in the area becoming more aware about prostate cancer. Patients in Asia Pacific, particularly in India, are using more hormone treatment drugs such antiandrogens.

Key Industry Players Analysis:

To increase their market position in the global prostate cancer therapeutics market business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.         

• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Ipsen Pharma
• Astellas Pharma Inc.
• Sanofi
• AstraZeneca
• Bayer AG
• Merck & Co., Inc.
• Valeant Pharmaceuticals International, Inc.
• Pfizer Inc.

Latest Development:

• In April 2022, The Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit will begin operations to improve prostate health in the Black community, according to the Milton and Carroll Petrie Department of Urology at Mount Sinai.
• In March 2022, For the treatment of adult patients with a specific kind of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, the United States Food and Drug Administration approved Novartis' Pluvicto (lutetium Lu 177 vipivotide tetraxetan).

Report Metrics

Report Attribute	Details
Study Period	2022-2030
Base year	2022
CAGR (%)	8%
Market Size	10,600 billion in 2022
Projection period	2023-2030
Projection unit	Value (USD)
Segments covered	By Drug Type, By Distribution Channel, and By Region.
Report Scope	Revenue Projection, competitive landscape, company ranking, growth factors, and trends
Companies covered	Sinopec Corp, China National Petroleum Corporation, HollyFrontier Corporation, BP P.L.C, Nippon Seiro Co., Ltd, Baker Hughes Company, Exxon Mobil Corporation, Sasol Limited, The International Group, Inc., Evonik Industries AG, BASF SE, Dow, Honeywell International Inc., Royal Dutch Shell P.L.C, and Mitsui Chemicals, Inc.
By Drug Type	Chemotherapy Targeted Therapy Hormonal Therapy Immunotherapy Others
By Distribution Channel	Online Pharmacies Hospital Pharmacies Drug Stores Retail Pharmacies
Regional scope	North America Europe Asia-Pacific South America Middle East and Africa

Scope of the Report

Global Prostate Cancer Therapeutics Market  By Drug Type:

• Chemotherapy
• Targeted Therapy
• Hormonal Therapy
• Immunotherapy
• Others

Global Prostate Cancer Therapeutics Market By Distribution Channel:

• Online Pharmacies
• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies

Global Prostate Cancer Therapeutics Market By Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political Factors- The prostate cancer therapeutics market should thoroughly analyse the taxation policies that are relevant to the business before deciding whether to expand. Industries that are high priorities for the government will benefit more from tax policy. Many developing nations' governments currently want to cut business taxes in an effort to draw in foreign direct investment. prostate cancer therapeutics market ought to take into account these nations since their low tax rates will make it simpler to turn a profit and spend in R&D, innovation, and new product development projects.

Economic Factors- Exchange rate fluctuations can have an impact on a company's profitability. In order to accurately predict exchange rate variations and prevent unintended trade and business performance implications, the prostate cancer therapeutics market should do this research. A high interest rate means that the prostate cancer therapeutics market will have to make payments at a high rate of interest, increasing the overall cost of the loans received. For the prostate cancer therapeutics market, achieving growth goals in mature businesses close to saturation can be more difficult. Therefore, when selecting the nations for international expansion, the industry lifecycle stage must be taken into account.

Social Factors- Respect for hierarchy and social class stratification are two significant social characteristics that might affect the prostate cancer therapeutics market's commercial, marketing, and human resource management initiatives. When entering nations with high power distance, the prostate cancer therapeutics market is most comfortable in hierarchical structures with formal work cultures. The requirement for efficient market segmentation techniques is also indicated by increased social stratification because the prostate cancer therapeutics market cannot target many categories from various social classes using the same marketing mix.

Technological Factors- prostate cancer therapeutics market should favor nations with advanced technology infrastructure since these nations make it simpler for businesses to pursue goals like cost reduction, innovation, and value creation. A well-developed technological infrastructure also shows that it will be more difficult for the prostate cancer therapeutics market to use technology to gain a sustained competitive advantage because it might be easily duplicated by rivals. Technological innovation's velocity and progress can impact the market and industry as a whole. prostate cancer therapeutics market will be able to comprehend the rate of new product creation, the length of the product life cycle, and the unique features that consumers choose by researching the upcoming technological innovation trends. prostate cancer therapeutics market can determine whether switching to e-commerce will be more advantageous than starting a physical store by doing research on consumers' sentiments regarding cutting-edge, emerging digital technology.

Environmental Factors- Extreme weather must be used to increase the cost of operations in the prostate cancer therapeutics market sector in order to boost supply chain flexibility. Due to continued environmental agency inspections, the operational costs of the prostate cancer therapeutics market are also rising. Waste management has become more crucial for industries like the prostate cancer therapeutics market, especially for facilities close to cities. For the removal of trash in urban areas, the Japanese government has developed strict regulations. Recycling is quickly moving from being a good practise to the norm in Japan's economy. The market for prostate cancer therapeutics must make preparations in order to adhere to regulations and requirements in the Basic Materials sector.

Legal Factors- A broad category of laws protecting employees' rights, including those to a fair salary, equality, equity, inclusion, fairness, and their physical and mental safety, is known as employment law. While some nations lack efficient enforcement of employment laws, others have harsh penalties for violating any of the specified rights of employees. prostate cancer therapeutics market should safeguard the safety of the working environment while entering or operating in such nations. There must be appropriate systems in place to prevent both direct and indirect discrimination. In the continuous competition for talent, effective compliance with employment rules can aid the prostate cancer therapeutics market in enhancing its employer brand reputation, which is critical for luring and keeping top personnel in the market.

1. Introduction
   • 1. Objectives of the Study
   • 2. Market Definition
   • 3. Research Scope
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
   • 1. Porter’s Five Forces Analysis
   • 2. Value Chain Analysis
   • 3. Top Investment Pockets
     • 3.1. Market Attractiveness Analysis By Product
     • 3.2. Market Attractiveness Analysis By Distribution Channel
     • 3.3. Market Attractiveness Analysis By Region
   • 4. Industry Trends
5. Market Dynamics
   • 1. Market Evaluation
   • 2. Drivers
     • 2.1. Rise in Prevalence
   • 3. Restraints
     • 3.1. High Cost
   • 4. Opportunities
     • 4.1. Rise in Government Initiatives
   • 5. Challenges
     • 5.1. Some Disadvantages

6. Global Prostate Cancer Therapeutics Market Analysis and Projection, By Product
   • 1. Segment Overview
   • 2. Chemotherapy
   • 3. Targeted Therapy
   • 4. Hormonal Therapy
   • 5. Immunotherapy
   • 6. Others
7. Global Prostate Cancer Therapeutics Market Analysis and Projection, By Distribution Channel
   • 1. Segment Overview
   • 2. Online Pharmacies
   • 3. Hospital Pharmacies
   • 4. Drug Stores
   • 5. Retail Pharmacies
8. Global Prostate Cancer Therapeutics Market Analysis and Projection, By Regional Analysis
   • 1. Segment Overview
   • 2. North America
     • 2.1. U.S.
     • 2.2. Canada
     • 2.3. Mexico
   • 3. Europe
     • 3.1. Germany
     • 3.2. France
     • 3.3. U.K.
     • 3.4. Italy
     • 3.5. Spain
   • 4. Asia-Pacific
     • 4.1. Japan
     • 4.2. China
     • 4.3. India
   • 5. South America
     • 5.1. Brazil
   • 6. Middle East and Africa
     • 6.1. UAE
     • 6.2. South Africa

9. Global Prostate Cancer Therapeutics Market-Competitive Landscape
   • 1. Overview
   • 2. Market Share of Key Players in the Prostate Cancer Therapeutics Market
     • 2.1. Global Company Market Share
     • 2.2. North America Company Market Share
     • 2.3. Europe Company Market Share
     • 2.4. APAC Company Market Share
   • 3. Competitive Situations and Trends
     • 3.1. Technology Launches and Developments
     • 3.2. Partnerships, Collaborations, and Agreements
     • 3.3. Mergers & Acquisitions
     • 3.4. Expansions

10. Company Profiles
    • Sinopec Corp
      • 1.1. Business Overview
      • 1.2. Company Snapshot
      • 1.3. Company Market Share Analysis
      • 1.4. Company Technology Portfolio
      • 1.5. Recent Developments
      • 1.6. SWOT Analysis
    • China National Petroleum Corporation
      • 2.1. Business Overview
      • 2.2. Company Snapshot
      • 2.3. Company Market Share Analysis
      • 2.4. Company Technology Portfolio
      • 2.5. Recent Developments
      • 2.6. SWOT Analysis
    • HollyFrontier Corporation
      • 3.1. Business Overview
      • 3.2. Company Snapshot
      • 3.3. Company Market Share Analysis
      • 3.4. Company Technology Portfolio
      • 3.5. Recent Developments
      • 3.6. SWOT Analysis
    • BP P.L.C
      • 4.1. Business Overview
      • 4.2. Company Snapshot
      • 4.3. Company Market Share Analysis
      • 4.4. Company Technology Portfolio
      • 4.5. Recent Developments
      • 4.6. SWOT Analysis
    • Nippon Seiro Co., Ltd
      • 5.1. Business Overview
      • 5.2. Company Snapshot
      • 5.3. Company Market Share Analysis
      • 5.4. Company Technology Portfolio
      • 5.5. Recent Developments
      • 5.6. SWOT Analysis
    • Baker Hughes Company
      • 6.1. Business Overview
      • 6.2. Company Snapshot
      • 6.3. Company Market Share Analysis
      • 6.4. Company Technology Portfolio
      • 6.5. Recent Developments
      • 6.6. SWOT Analysis
    • Exxon Mobil Corporation
      • 7.1. Business Overview
      • 7.2. Company Snapshot
      • 7.3. Company Market Share Analysis
      • 7.4. Company Technology Portfolio
      • 7.5. Recent Developments
      • 7.6. SWOT Analysis
    • Sasol Limited
      • 8.1. Business Overview
      • 8.2. Company Snapshot
      • 8.3. Company Market Share Analysis
      • 8.4. Company Technology Portfolio
      • 8.5. Recent Developments
      • 8.6. SWOT Analysis
    • The International Group, Inc.
      • 9.1. Business Overview
      • 9.2. Company Snapshot
      • 9.3. Company Market Share Analysis
      • 9.4. Company Technology Portfolio
      • 9.5. Recent Developments
      • 9.6. SWOT Analysis
    • Evonik Industries AG
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • BASF SE
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Dow
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Honeywell International Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Royal Dutch Shell P.L.C
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Mitsui Chemicals, Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
2. Global Chemotherapy, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
3. Global Targeted Therapy, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
4. Global Hormonal Therapy, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
5. Global Immunotherapy, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
6. Global Others, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
7. Global Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
8. Global Online Pharmacies, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
9. Global Hospital Pharmacies, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
10. Global Drug Stores, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
11. Global Retail Pharmacies, Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
12. Global Prostate Cancer Therapeutics Market, By Region, 2023–2030 (USD Million)
13. North America Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
14. North America Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
15. USA Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
16. USA Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
17. Canada Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
18. Canada Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
19. Mexico Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
20. Mexico Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
21. Europe Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
22. Europe Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
23. Germany Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
24. Germany Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
25. France Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
26. France Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
27. UK Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
28. UK Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
29. Italy Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
30. Italy Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
31. Spain Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
32. Spain Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
33. Asia Pacific Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
34. Asia Pacific Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
35. Japan Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
36. Japan Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
37. China Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
38. China Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
39. India Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
40. India Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
41. South America Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
42. South America Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
43. Brazil Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
44. Brazil Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
45. Middle East and Africa Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
46. Middle East and Africa Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
47. UAE Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
48. UAE Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)
49. South Africa Prostate Cancer Therapeutics Market, By Product, 2023–2030 (USD Million)
50. South Africa Prostate Cancer Therapeutics Market, By Distribution Channel 2023–2030 (USD Million)

List of Figures 

1. Global Prostate Cancer Therapeutics Market Segmentation
2. Prostate Cancer Therapeutics Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Prostate Cancer Therapeutics Market Attractiveness Analysis By Product
9. Global Prostate Cancer Therapeutics Market Attractiveness Analysis By Distribution Channel
10. Global Prostate Cancer Therapeutics Market Attractiveness Analysis By Region
11. Global Prostate Cancer Therapeutics Market: Dynamics
12. Global Prostate Cancer Therapeutics Market Share By Product (2023 & 2030)
13. Global Prostate Cancer Therapeutics Market Share By Distribution Channel (2023 & 2030)
14. Global Prostate Cancer Therapeutics Market Share by Regions (2023 & 2030)
15. Global Prostate Cancer Therapeutics Market Share by Company (2021)